Latest Ratios: P/E Ratio -1.0x · EV/EBITDA N/A · ROE -44.7%. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $333M | $390M | $175M | — | — | — |
| Enterprise Value | $-37675447 | $19M | $173M | — | — | — |
| P/E Ratio → | -0.97 | — | 22.83 | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | 0.32 | 0.95 | 0.93 | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | -44.7% | -44.7% | -78.7% | — | — | — |
| ROA | -41.7% | -41.7% | -76.3% | -27100.6% | -2.4% | -30.1% |
| ROIC | -96.3% | -96.3% | -64.9% | -350050.4% | -13.3% | — |
| ROCE | -48.0% | -48.0% | -83.3% | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | 1.19 |
| Net Debt / Equity | — | -0.90 | -0.01 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | 1.19 |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — |
Net cash position: cash ($374M) exceeds total debt ($3M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 12.14 | 12.14 | 10.40 | — | — | — |
| Quick Ratio | 12.14 | 12.14 | 10.40 | — | — | — |
| Cash Ratio | 12.14 | 12.14 | 9.05 | — | — | — |
| Asset Turnover | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 4.4% | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $31M | $17M | $20M | $20M | $20M |
Includes 30+ ratios · 5 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BBOT stock.
BridgeBio Oncology Therapeutics Inc.'s current P/E ratio is -1.0x. The historical average is 22.8x.
BridgeBio Oncology Therapeutics Inc.'s return on equity (ROE) is -44.7%. The historical average is -61.7%.
Based on historical data, BridgeBio Oncology Therapeutics Inc. is trading at a P/E of -1.0x. Compare with industry peers and growth rates for a complete picture.
Key Metrics
Top Statement Risk
Pre-revenue cash burn with near-term funding gap
Metrics are mathematically derived from official filings.
Liquidity Cushion Rapidly Consumed
BBOT's current ratio has collapsed from a peak of 90.42 in Q1 2024 to 4.69 by Q2 2026, indicating the initial capital buffer is being rapidly consumed to fund pre-commercial operations without any revenue offset.
The trajectory of the current ratio, which equals the quick ratio as inventory is absent, illustrates the company's single-minded consumption of its cash reserves. This is a direct mathematical consequence of the accelerating free cash flow burn detailed in prior analysis, and the declining ratio underscores the finite nature of the existing cash balance relative to the pace of operational spending.
Negligible Leverage, Equity-Funded Burn
With a debt-to-equity ratio of just 0.01 as of Q2 2026, BBOT maintains an exceptionally conservative capital structure, indicating its substantial operational losses are being funded entirely through equity rather than debt financing.
This minimal leverage profile is characteristic of a pre-revenue biotechnology firm, where the absence of cash flow makes traditional debt financing inaccessible or prohibitively expensive. The low D/E ratio suggests that any future need for capital will likely be met through equity issuance, potentially diluting existing shareholders, rather than through adding financial leverage and interest burden.
Negative Returns Reflect Pre-Revenue Status
BBOT's return on equity has been consistently negative, reaching -16.2% in Q2 2026, which is a mathematical inevitability for a company with a substantial negative accumulated deficit and zero revenue to generate positive net income.
The negative ROE and ROIC figures are not indicative of operational inefficiency but rather confirm the company's stage in the business lifecycle. The capital invested is currently being deployed to develop assets with future optionality, not to generate near-term returns. The consistency of these negative metrics underscores the singular focus on pipeline advancement over current profitability.
Peer Comparison Highlights Stage Dichotomy
Among biotech peers, BBOT's negative ROE and minimal leverage are more aligned with clinical-stage peers like KYMR and RVMD, contrasting sharply with profitable commercial-stage peers like KRYS and AUPH, suggesting its valuation is tied to pipeline promise rather than current financials.
The peer set reveals a stark divide. Companies with approved products like Krystal Biotech and Aurinia Pharmaceuticals demonstrate positive returns on capital and profitability, setting a potential future benchmark. BBOT's financial profile, with its negative returns and liquidity drawdown, is more reminiscent of peers like Kymera Therapeutics, positioning it in the higher-risk, higher-potential-reward category of the sector.
Liquidity Ratio Misleads on Runway
The most commonly misapplied ratio to BBOT is the current ratio, which at 4.69 appears to indicate ample liquidity, but fundamentally obscures the critical reality that this cushion is being rapidly depleted by a significant, unfinanced cash burn with no revenue.
For a pre-revenue, high-burn company, the static current ratio is a misleading snapshot of a dynamic problem. It fails to incorporate the quarterly rate of cash consumption. The analysis should instead focus on the implied runway, calculated by dividing the cash balance of $54.1 million (Q2 2026) by the approximate quarterly cash burn, which suggests a near-term funding gap may emerge. The ratio's decline over time is the more telling metric, signaling the exhaustion of the initial capital raise.